- Home
- PDD vs AMGN Comparison
PDD vs AMGN Comparison
Compare PDD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | AMGN |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0B | 181.7B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | PDD | AMGN |
|---|---|---|
| Price | $113.16 | $328.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 14 |
| Target Price | $134.30 | ★ $315.31 |
| AVG Volume (30 Days) | ★ 7.7M | 3.0M |
| Earning Date | 11-18-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 3.07% |
| EPS Growth | N/A | ★ 65.12 |
| EPS | 9.68 | ★ 12.93 |
| Revenue | ★ $58,790,822,784.00 | $35,971,000,000.00 |
| Revenue This Year | $10.73 | $10.85 |
| Revenue Next Year | $14.94 | $1.77 |
| P/E Ratio | ★ $11.76 | $25.41 |
| Revenue Growth | ★ 12.48 | 10.56 |
| 52 Week Low | $87.11 | $257.05 |
| 52 Week High | $139.41 | $346.38 |
Technical Indicators
Market Signals| Indicator | PDD | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 50.14 |
| Support Level | $112.03 | $325.83 |
| Resistance Level | $115.34 | $334.38 |
| Average True Range (ATR) | 2.66 | 4.89 |
| MACD | 0.99 | -0.24 |
| Stochastic Oscillator | 68.17 | 69.77 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.